Compare ESOA & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESOA | TLSI |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.0M | 270.2M |
| IPO Year | 2006 | 2020 |
| Metric | ESOA | TLSI |
|---|---|---|
| Price | $13.84 | $5.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $21.00 | $7.00 |
| AVG Volume (30 Days) | 115.2K | ★ 206.0K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $122,465,826.00 | $45,151,000.00 |
| Revenue This Year | $9.22 | $35.45 |
| Revenue Next Year | $3.77 | $37.58 |
| P/E Ratio | $91.24 | ★ N/A |
| Revenue Growth | 2.74 | ★ 53.41 |
| 52 Week Low | $7.84 | $2.20 |
| 52 Week High | $19.94 | $7.95 |
| Indicator | ESOA | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 34.46 | 76.86 |
| Support Level | $12.65 | $3.77 |
| Resistance Level | $14.69 | $6.33 |
| Average True Range (ATR) | 0.79 | 0.36 |
| MACD | -0.03 | 0.13 |
| Stochastic Oscillator | 9.69 | 95.95 |
Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is predominantly engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical, and automotive industries and does incidental work such as water and sewer projects. Energy Service's other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services, and other services related to pipeline construction.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.